[Severe enteropathy with villous atrophy olmesartan medoxomil-associated]

Therapie. 2013 Nov-Dec;68(6):419-21. doi: 10.2515/therapie/2013057. Epub 2013 Nov 11.

[Article in French]

Authors

Débora Nunge¹, Matthieu Eoche², Mathurin Fumery², Eric Nguyen-Khac², Valérie Gras¹, Michel Andréjak³

Affiliations

¹ Centre régional de Pharmacovigilance, Service de Pharmacologie clinique, CHU Amiens Sud, Amiens, France.
² Service d'Hépato-gastroentérologie, CHU Amiens Nord, Amiens, France.
³ Centre régional de Pharmacovigilance, Service de Pharmacologie clinique, CHU Amiens Sud, Amiens, France - Inserm U1088, Université Picardie Jules Verne, Faculté de Pharmacie, Amiens, France.

PMID: 24246126
DOI: 10.2515/therapie/2013057

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Aged, 80 and over
Angiotensin II Type 1 Receptor Blockers / adverse effects*
Atrophy
Diarrhea / chemically induced*
Female
Humans
Imidazoles / adverse effects*
Intestinal Diseases / chemically induced*
Intestinal Diseases / pathology
Microvilli / pathology
Olmesartan Medoxomil
Severity of Illness Index
Tetrazoles / adverse effects*

Substances

Angiotensin II Type 1 Receptor Blockers
Imidazoles
Tetrazoles
Olmesartan Medoxomil